Press-release for stocks for GILD

Prices are updated after-hours

symbols : GILD

save search

Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
Published: 2023-10-19 (Crawled : 10:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -15.87% | O: -0.75% H: 1.01% C: -0.8%
biktarvy treatment hiv

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
Published: 2023-10-18 (Crawled : 11:00) - globenewswire.com
HOOK | $0.739 -3.4% 8.4M

Health Technology

| 47.23% | O: 3.19% H: 0.98% C: -1.98%
GILD | $66.55 -0.72% 1.6M

Health Technology

| -16.71% | O: -0.01% H: 0.3% C: -0.99%
hepatitis pharma vaccine publication sciences preclinical collaboration virus

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -16.71% | O: -0.01% H: 0.3% C: -0.99%
europe sciences hiv program trial

Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Published: 2023-10-12 (Crawled : 23:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -12.9% | O: -0.1% H: 0.3% C: -0.16%
sciences financial results

If you purchased brand or generic Truvada or Atripla directly from the manufacturer, you may receive a payment from a class action settlement. Under the settlement, Gilead agreed to pay $246,750,000 into a Settlement Fund
Published: 2023-10-09 (Crawled : 12:00) - prnewswire.com
GILD | $66.55 -0.72% 1.6M

Health Technology

| -10.32% | O: 0.05% H: 0.75% C: 0.37%
payment

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Published: 2023-10-03 (Crawled : 13:30) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -9.54% | O: -1.2% H: 0.9% C: 0.08%
covid-19 hiv

THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON
Published: 2023-09-22 (Crawled : 21:00) - prnewswire.com
GILD | $66.55 -0.72% 1.6M

Health Technology

| Email alert Add to watchlist
symposium awards

Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -11.42% | O: 0.25% H: 0.38% C: -0.32%
yescarta t-cell treatment response therapy study

Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Published: 2023-09-13 (Crawled : 14:30) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -51.54% | O: -2.2% H: 0.9% C: -1.8%
GILD | $66.55 -0.72% 1.6M

Health Technology

| -12.72% | O: 0.26% H: 0.69% C: 0.4%
FULC | $7.32 -1.61% 26K

Health Technology

| 42.53% | O: -0.19% H: 0.0% C: -8.83%
BCTX | $2.2 9K

Professional, Scientific, and T...

| -55.91% | O: -1.12% H: 3.87% C: -1.94%
RNA | News M | $25.12 -0.08% 160K

Health Technology

| 248.68% | O: 1.25% H: 3.01% C: -2.6%
fda biotech momentum

Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities
Published: 2023-09-09 (Crawled : 04:20) - prnewswire.com
VTRS | News A | $11.34 -0.18% 900K

Health Technology

| Email alert Add to watchlist
GSK | News | $40.73 -1.24% 360K

Health Technology

| Email alert Add to watchlist
BMY | $48.64 -0.71% 2.3M

Health Technology

| Email alert Add to watchlist
GILD | $66.55 -0.72% 1.6M

Health Technology

| Email alert Add to watchlist
ABBV | News | $168.1 -0.85% 670K

Health Technology

| Email alert Add to watchlist
GLAXF | News | $19.54 2.6K

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380

Health Technology

| Email alert Add to watchlist
JNJ | News | $147.27 -1.53% 2.3M

Health Technology

| Email alert Add to watchlist
report antiviral therapeutics market

Gilead Prices $2 Billion of Senior Unsecured Notes
Published: 2023-09-08 (Crawled : 08:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -9.35% | O: 2.95% H: 0.62% C: -0.16%

Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million
Published: 2023-09-06 (Crawled : 15:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -10.82% | O: -0.05% H: 0.03% C: -1.17%
series total deal

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
MGNX | $15.96 -1.66% 110K

Health Technology

| 233.95% | O: 3.09% H: 3.59% C: 1.4%
GILD | $66.55 -0.72% 1.6M

Health Technology

| -12.55% | O: 0.39% H: 0.06% C: -2.33%
research program milestone

Global Neutropenia Market to Reach $5.77 Billion by 2028 with a CAGR of 6.2%: Growing Prevalence of Leukemia Drives Demand
Published: 2023-08-29 (Crawled : 17:00) - prnewswire.com
BAX | $40.705 -0.77% 280K

Health Technology

| -1.51% | O: 0.48% H: 1.4% C: 1.15%
SNY | News | $46.82 -1.82% 510K

Health Technology

| -12.54% | O: 0.34% H: 0.0% C: 0.0%
GILD | $66.55 -0.72% 1.6M

Health Technology

| -12.99% | O: 0.27% H: 1.29% C: 1.24%
BIIB | $202.05 4.59% 1.1M

Health Technology

| -27.12% | O: 0.11% H: 1.06% C: 1.0%
reach global growing leukemia market

FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Published: 2023-08-24 (Crawled : 18:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -12.99% | O: 0.27% H: 1.15% C: -1.19%
covid-19 veklury fda treat

Everest Medicines Announces Interim Results for First Half of 2023
Published: 2023-08-24 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.185 -0.51% 6.6M

Health Technology

| -28.21% | O: -0.5% H: 0.45% C: -0.86%
GILD | $66.55 -0.72% 1.6M

Health Technology

| -12.99% | O: 0.27% H: 1.15% C: -1.19%
CALT | $18.2 540

Health Technology

| 2.25% | O: -4.72% H: 0.0% C: 0.0%
results

Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
Published: 2023-08-21 (Crawled : 13:20) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology

| -11.66% | O: -0.28% H: 0.78% C: 0.36%
aml

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Published: 2023-08-18 (Crawled : 22:00) - biospace.com/
GILD | $66.55 -0.72% 1.6M

Health Technology